Get Started
Valve Disease2018New England Journal of Medicine

COAPT

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation

Sample Size
614
Study Design
Multicenter, randomized, controlled, open-label trial with independent adjudication
Year Published
2018
Category
Valve Disease

Clinical Question

Does transcatheter mitral valve repair with MitraClip reduce heart failure hospitalizations and mortality in patients with heart failure and moderate-to-severe or severe secondary (functional) mitral regurgitation despite guideline-directed medical therapy?

Population

Patients with heart failure (NYHA class II-IV), left ventricular ejection fraction 20-50%, and moderate-to-severe or severe secondary mitral regurgitation despite maximally tolerated guideline-directed medical therapy (GDMT).

Intervention

Transcatheter mitral valve repair with MitraClip plus GDMT

Control

Guideline-directed medical therapy (GDMT) alone

Primary Endpoint

All hospitalizations for heart failure within 24 months

Key Findings

1

Heart failure hospitalizations at 24 months were 35.8% with MitraClip vs 67.9% with GDMT alone (HR 0.53; 95% CI, 0.40-0.70; p<0.001).

2

All-cause mortality at 24 months was 29.1% with MitraClip vs 46.1% with GDMT (HR 0.62; 95% CI, 0.46-0.82; p<0.001).

3

Quality of life (KCCQ) improved significantly more in the MitraClip group at all time points.

4

MR severity was reduced to moderate or less in 94.8% of MitraClip patients at 12 months.

5

Procedural safety was excellent, with 96.6% freedom from device-related complications at 12 months.

Impact on Clinical Practice

COAPT was a transformative trial that established transcatheter edge-to-edge repair (TEER) with MitraClip as a life-saving therapy for patients with heart failure and severe secondary mitral regurgitation. The results were remarkable: both the primary endpoint of heart failure hospitalizations and the secondary endpoint of mortality showed large, highly significant reductions. The trial was particularly impactful because it addressed a population with no good surgical options. Surgical mitral valve repair for functional MR had shown disappointing results, and these patients had persistently poor outcomes despite optimal medical therapy. MitraClip provided a minimally invasive solution with dramatic clinical benefit. COAPT's success was attributed in part to careful patient selection: enrollees had "disproportionate" MR (severe regurgitation relative to left ventricular size), which contrasted with the MITRA-FR population. This distinction, formalized by concept of proportionate versus disproportionate MR, became central to clinical decision-making.

Guideline Impact

COAPT led to the 2020 ACC/AHA Class 2a recommendation for transcatheter edge-to-edge repair in patients with heart failure, reduced LVEF, and severe secondary MR despite optimized GDMT. It was the primary evidence base for the FDA expanded indication of MitraClip for secondary MR in 2019.

Limitations

Strict eligibility criteria limit generalizability; only about 5% of screened patients were enrolled.

Open-label design may have influenced clinical management and endpoint ascertainment in the control group.

The concept of "disproportionate MR" as a selection criterion, while biologically plausible, requires further validation in broader populations.

Sandeep M. Patel, MD
Reviewed by Sandeep M. Patel, MD
Structural & Interventional Cardiologist

How Does This Trial Apply to Your Case?

Clinical trials inform guidelines, but every patient is unique. Our Heart Team evaluates how landmark evidence applies to your specific anatomy, risk profile, and preferences.

Get a Second Opinion

Related Trials

MITRA-FR
2018 · New England Journal of Medicine
mitral regurgitationheart failuremitraclip vs medical therapy
Stay informed.
Expert cardiac surgery insights from the WhiteGloveMD Heart Team, delivered to your inbox.
No spam. Unsubscribe anytime. HIPAA-compliant.